BofA analyst Jason Gerberry raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $182 from $172 and keeps a Buy rating on the shares. Jazz reported in-line 3Q revenue and a sizeable ...
Some results have been hidden because they may be inaccessible to you